Form 4: SERA Director Sells Shares Under 10b5-1 Plan

SERA Prognostics Director Sandra AJ Lawrence sold 1,560 shares of Class A Common Stock at a weighted average price of $1.95 per share under a pre-arranged trading plan.

Summary

• Sandra AJ Lawrence, a Director of SERA Prognostics, Inc., disposed of 1,560 shares of Class A Common Stock.
• The transaction occurred on March 6, 2026.
• The shares were sold at a weighted average price of $1.95 per share, with individual transaction prices ranging from $1.90 to $2.00.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Lawrence on June 10, 2025.
• Following this transaction, Ms. Lawrence beneficially owns 18,033 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a Rule 10b5-1 plan suggests a pre-determined financial management decision rather than a reaction to recent company performance or outlook.

Positives

• The transaction was effected pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on new, non-public information.

Negatives

• A director selling shares, even under a pre-arranged plan, can be perceived by some investors as a reduction in direct alignment with shareholder interests.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a routine disclosure for public companies. While not inherently negative, it's often scrutinized by investors for potential signals about management's confidence in the company's future prospects, especially when compared to broader industry trends or peer activity.

Stakeholder Impact

• Shareholders: The sale slightly reduces the director's direct equity alignment with shareholder interests, though the pre-planned nature of the transaction mitigates immediate concern.

Key Dates

Recommendation

The transaction is a pre-scheduled sale under a 10b5-1 plan, which typically indicates personal financial planning rather than a change in the company's fundamental outlook. While insider selling can be a minor negative, this specific context suggests no immediate reason to alter an investment thesis based solely on this filing. Investors should continue to monitor SERA's operational and financial performance.

Keywords

SERA Prognostics, SERA, Form 4, Insider Trading, Stock Sale, Director, Sandra AJ Lawrence, 10b5-1 Plan, Equity Transaction